Inflammatory Disease News and Research

RSS

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

Medical professionals compare different treatment options for Neuromyelitis optica

In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system. It turned out that the best results were not achieved with conventional steroid therapy.

26 Nov 2015

Ultrasound can help identify patients at increased risk of future stroke

Ultrasound, a non-invasive technique commonly used to study the presence of atherosclerosis disease in blood vessels, can be used to identify patients at increased risk of future stroke who could benefit from surgery. Since surgical treatment to prevent stroke is only considered beneficial to some, ultrasound can prove useful in preventing unnecessary surgical intervention, new research at Umeå University in Sweden shows.

25 Nov 2015

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

ProMetic Life Sciences Inc. announced today that it has entered into a strategic partnership with ProThera Biologics Inc. for the development and commercialization of human plasma-derived Inter-alpha Inhibitor Proteins.

19 Nov 2015

TTUHSC nephrologists to help find new treatment for lupus nephritis

Nephrologists at Texas Tech University Health Science Center El Paso have been invited to participate in a national consortium that's investigating the key causes of lupus nephritis -- an autoimmune disease that can cause kidney failure.

17 Nov 2015

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.

9 Nov 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

WSU collaborates with Botanisol to study and develop new anti-inflammatory drug

Work on a new anti-inflammatory drug developed from the medicinal/spice plant turmeric recently received funding from a $225,000 grant from the National Institutes of Health National Center for Complementary and Integrative Health.

28 Oct 2015

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older.

19 Oct 2015

Tamoxifen drug clears MRSA, reduces mortality

Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling them to respond to, ensnare and kill bacteria in laboratory experiments. Tamoxifen treatment in mice also enhances clearance of the antibiotic-resistant bacterial pathogen MRSA and reduces mortality.

13 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the efficacy and safety of TECFIDERA® (dimethyl fumarate) across a broad range of people with relapsing-remitting multiple sclerosis (RRMS).

7 Oct 2015

OJ-Bio to showcase new smartphone-enabled diagnostic testing device at Medica 2015

Advanced smartphone-enabled medical device technology for the rapid and cost-effective detection of infectious diseases will be featured at this year’s prestigious Medica show.

29 Sep 2015

Researchers use new software tool to identify genetic overlaps between palmitoleic acid and Crohn's disease

Some research has suggested that omega-3 fatty acids, abundant in fish oils, can relieve inflammation in Crohn's disease. But a new study using software developed by Duke scientists hints that we should be paying closer attention to what the other omegas -- namely, omega-6 and omega-7 -- are doing to improve or worsen the disease.

16 Sep 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.

6 Aug 2015

Prokarium receives funding to complete pre-clinical development of new Chlamydia vaccine

Prokarium Ltd, a biotechnology company developing transformational oral vaccines, today announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.

4 Aug 2015

New MS therapies associated with risks and side effects, require active management strategy

Advances in the treatment of Multiple Sclerosis have been good news for patients, but side effects and risks mean that an active management strategy and constant monitoring are essential.

3 Aug 2015

Study points to new treatment strategies for liver cancer

A new study by researchers at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute has found that blocking the activity of a key immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer.

25 Jul 2015